jnanatx.comHealthcare / BioTech & PharmaFounded: 2017Funding to Date: $414.4MM
Jnana Therapeutics is a drug discovery company focusing on small molecule therapies for phenylketonuria along with other immune related conditions.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
11/15/2022 | Series C-1 | $60MM | $xx.xx | $292.93MM | Avalon Ventures, Bain Capital, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
94,114,208
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Avalon Ventures, Bain Capital, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures
|
||||||
11/15/2022 | Series C-2 | $47MM | $xx.xx | $292.93MM | Avalon Ventures, Bain Capital, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
52,659,140
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Avalon Ventures, Bain Capital, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures
|
||||||
08/18/2021 | Series B | $50MM | $xx.xx | $175.22MM | Abbvie Ventures, Avalon Ventures, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
52,785,490
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abbvie Ventures, Avalon Ventures, Pfizer Ventures, Polaris Partners, Ra Capital Management, Versant Ventures
|
||||||
12/14/2017 | Series A-1 | $17.25MM | $xx.xx | $134.9MM | Abbvie Ventures, Avalon Ventures, Pfizer R&D Innovate, Polaris Partners, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
34,500,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abbvie Ventures, Avalon Ventures, Pfizer R&D Innovate, Polaris Partners, Versant Ventures
|
||||||
12/14/2017 | Series A | $32.95MM | $xx.xx | $134.9MM | Abbvie Ventures, Avalon Ventures, Pfizer R&D Innovate, Polaris Partners, Versant Ventures | |
Price per Share
$xx.xx
Shares Outstanding
32,950,000
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
3.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Abbvie Ventures, Avalon Ventures, Pfizer R&D Innovate, Polaris Partners, Versant Ventures
|